

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 8 March 2021

Situation Report No. 244 - Kingdom of Bahrain

9th of March, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	116,521,281	2,589,548	6,650,125	147,689
New	354,629	7,020	33,285	405


Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
	Total	127,201	120,489	473	6,293	57
New	653	718	1	-	-	15,959


HIGHLIGHTS

- The Mortality was a 54 years old Female expatriate.
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 8 March 2021 for the first dose (309,741) and for the second dose (202,679).
- Ministry of Health (MOH) Undersecretary praised competence and dedication of the Bahraini health workers in confronting the Coronavirus pandemic.
- MOH Undersecretary indicated that priority in recruitment is given to the Bahraini volunteer health workers based on vacancies corresponding to their qualifications.
- Public Security Assistant Chief stressed individual responsibility in combating COVID-19, urging compliance with mandatory precautionary measures.
- Last month recorded the highest COVID-19 deaths ever since the onset of the pandemic in Bahrain.
- A study revealed that COVID-19 carriers in Bahrain who are asymptomatic are the 'silent spreaders' transmitting the virus at a high rate.
- A total of 45 people tested positive for COVID-19 after contact tracing of two infected individuals during random community screening.
- Multiple vaccines have been made available to achieve immunity and end the pandemic.
- Bahrain is piloting an internationally-recognized digital passport programme on global air travel.
- Over 80 government services have migrated to online last year due to the COVID-19 pandemic.
- Inmates in Bahrain can choose the vaccine they get.
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies; see link below.
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID19 spread accelerates, JHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for a COVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO: WHO Living Guideline: Theapeutics and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO: Issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=6649a76_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news-room/detail/09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue surveys: <https://www.who.int/publications/item/978-92-4-151258-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/34APN6G>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay: <https://bit.ly/2H0jvYf>
- WHO: Global TB progress a trisk: <https://bit.ly/46t19>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2DwwWQ>
- WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS: <https://bit.ly/34APN6G>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/315f89f>
- WHO: As COVID19 spread accelerates, JHR Emergency Committee urges focus on measures that work: <https://bit.ly/372006>
- WHO: The push for a COVID-19 vaccine: <https://bit.ly/3m3Sh4a>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3panK54>
- WHO: WHO Living Guideline: Theapeutics and COVID-19: <https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-HCFC_assessment-Products-2020.1
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: https://icr.who.int/polder/Downloads/WHO-2019-nCoV-health_workforce-2020.1-eng.pdf
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066533753>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: https://www.who.int/publications/item/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/news/item/18-12-2020-covid-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covid-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: [https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages)
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca: <https://www.who.int/news/item/04-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises>
- WHO: Rotavirus vaccines made available for use in humanitarian crises: <https://www.who.int/news/item/04-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises>

IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh